Another Diagnostic Behemoth is Born
With two major proposed mergers in one month, the diagnostics industry is finally seeking the kind of consolidation that its soothsayers predicted would happen for years.
You may also be interested in...
Pfizer has received European Commission approval for the firm’s Ruxience biosimilar to Roche’s MabThera brand, including as a treatment for rheumatoid arthritis, opening the door to a three-way biosimilar fight in the European Union.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
Investment from Janssen helps to validate the platform developed by the San Diego-based company.